Jane Street’s Gain Therapeutics GANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$421K Sell
216,883
-25,445
-11% -$55.4K ﹤0.01% 8449
2025
Q4
$780K Buy
242,328
+169,878
+234% +$453K ﹤0.01% 6684
2025
Q3
$128K Buy
+72,450
New +$122K ﹤0.01% 9994
2022
Q2
Sell
-11,722
Closed -$48K 10059
2022
Q1
$48K Buy
+11,722
New +$49K ﹤0.01% 9705
2021
Q2
Sell
-22,754
Closed -$339K 9973
2021
Q1
$339K Buy
+22,754
New +$299K ﹤0.01% 7497

Other funds holding GANX

Jane Street's GANX Position: Q1 2026 in Review

Jane Street reduced its Gain Therapeutics (GANX) stake by 11% in Q1 2026, selling an estimated $55.4K and leaving 216,883 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #8449.

Jane Street first reported a position in GANX in Q1 2021 and has held it in 5 quarters since. The position peaked at $780K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Jane Street held 216,883 shares of Gain Therapeutics worth $421K as of Q1 2026.
  • Jane Street sold 25,445 Gain Therapeutics shares in Q1 2026, an estimated $55.4K.
  • Gain Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8449 holding.
  • Jane Street first reported a position in Gain Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • Jane Street's Gain Therapeutics position peaked at $780K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.